Company intelligence / Profile preview

SoliPharma

Hangzhou, Zhejiang, Chinapharmasources.com ↗

Ownership: Private
Development stage: Other

Overview

SoliPharma has developed a diverse pipeline of over 30 topical products using its proprietary technology platform. The company provides comprehensive CDMO services, supporting global clients with pre-formulation, formulation, analytical testing, regulatory filings, and manufacturing. It has successfully completed work for 800+ clients worldwide across more than 2000 compounds at various clinical stages. The company’s facilities have passed US FDA GMP inspection with zero deficiencies, highlighting strong compliance capabilities.

Therapeutic areas: Dermatology
Modalities: Small moleculeTopical formulationTransdermal deliveryComplex generics
Industry: Contract Manufacturing Organization

Partnerships

Not specifically named; the company leverages global partnerships with API suppliers, contract manufacturers, and distributors. No major pharma/biotech partners are explicitly listed.

Beyond the preview

Go deeper on SoliPharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SoliPharma.

Explore the full profile